Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 33INDUSTRY 8NIH 5NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Prostatic Diseases 1Lung Neoplasms 1ATM Gene Mutation 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × talazoparib × Clear all
NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting
78 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT04173507 2024-09-03

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT03377556 2021-06-23

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
51 enrolled 18 charts

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡